Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Lymphoma, Large B-Cell, Diffuse 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Burkitt Lymphoma 2Brenner Tumor 2Breast Neoplasms 2

Interventions

pembrolizumab 5Cisplatin 5Platinum 4Pemetrexed 41,2-diaminocyclohexaneplatinum II citrate 4Nivolumab 3Cyclophosphamide 3fludarabine 2atezolizumab 2Ipilimumab 2Carboplatin 2tremelimumab 1sargramostim 1methoxyamine 1lenvatinib 1cediranib 1anetumab ravtansine 1UV1 vaccine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Interleukin-2 1Imprint II 1Immunotherapy, Adoptive 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Bevacizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × Disulfides × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡